Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to $65.5 million.

  • Anaptysbio's Net Cash Flow fell 4527.81% to $65.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.7 million, marking a year-over-year decrease of 14945.85%. This contributed to the annual value of $87.1 million for FY2024, which is 34648.45% up from last year.
  • Latest data reveals that Anaptysbio reported Net Cash Flow of $65.5 million as of Q3 2025, which was down 4527.81% from -$54.3 million recorded in Q2 2025.
  • Anaptysbio's 5-year Net Cash Flow high stood at $159.3 million for Q4 2021, and its period low was -$329.3 million during Q1 2022.
  • Moreover, its 5-year median value for Net Cash Flow was $9.7 million (2023), whereas its average is -$7.4 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 107743.38% in 2022, then surged by 144395.69% in 2024.
  • Quarter analysis of 5 years shows Anaptysbio's Net Cash Flow stood at $159.3 million in 2021, then crashed by 91.99% to $12.8 million in 2022, then fell by 24.22% to $9.7 million in 2023, then tumbled by 808.39% to -$68.5 million in 2024, then soared by 195.67% to $65.5 million in 2025.
  • Its last three reported values are $65.5 million in Q3 2025, -$54.3 million for Q2 2025, and -$24.4 million during Q1 2025.